Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms
Brain Neoplasms
Carboplatin
Carboplatin
Cisplatin
Cisplatin
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 6
Double-Blind Method
Double-Blind Method
Etoposide
Etoposide
Female
Female
Follow-Up Studies
Follow-Up Studies
Humans
Humans
Lung Neoplasms
Lung Neoplasms
Male
Male
Maximum Tolerated Dose
Maximum Tolerated Dose
Middle Aged
Middle Aged
Myeloid Cells
Myeloid Cells
Paclitaxel
Paclitaxel
Prognosis
Prognosis
Pyrimidines
Pyrimidines
Pyrroles
Pyrroles
Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Survival Rate
Survival Rate
Tissue Distribution
Tissue Distribution
authors with profiles
Raid Aljumaily